VENTANA PD-L1 predictive assays assess the degree and likelihood of potential patient benefit from corresponding PD-1/PD-L1 immunotherapies. The link between assay results and patient benefit has been established and verified in studies.
VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying urothelial carcinoma (UC) patients most likely to benefit from IMFINZI™ (durvalumab) [FDA approved in the US and CE mark]
Urothelial carcinoma [CE mark and FDA approved]
Empowering pathologists to answer PD-L1 questions
The VENTANA PD-L1 (SP263) Assay* is the clinical trial enrollment assay for IMFINZITM (durvalumab) and the only PD-L1 assay validated to assess UC patient treatment benefit from this PD-L1 inhibitor. Using a validated assay to determine PD-L1 status for immunotherapies is important. VENTANA PD-L1 (SP263) Assay equips pathologists by:
- Identifying urothelial carcinoma patients most likely to benefit from IMFINZI (durvalumab)
- Producing robust PD-L1 staining in both tumor cells (TC) and tumor-infiltrating immune cells (IC)
- Providing access to multiple immunotherapy options for different cancer types**
* In the US only available on the BenchMark ULTRA Instrument
** VENTANA PD-L1 (SP263) Assay is also CE marked for OPDIVO and KEYTRUDA in NSCLC
The PD-L1 immunologic checkpoint
About PD-L1